SI2217704T1 - Postopek za pospeševanje angiogeneze, vaskularizacije ali popravilo žil ali za zaviranje tumorske angiogeneze - Google Patents

Postopek za pospeševanje angiogeneze, vaskularizacije ali popravilo žil ali za zaviranje tumorske angiogeneze

Info

Publication number
SI2217704T1
SI2217704T1 SI200831774A SI200831774A SI2217704T1 SI 2217704 T1 SI2217704 T1 SI 2217704T1 SI 200831774 A SI200831774 A SI 200831774A SI 200831774 A SI200831774 A SI 200831774A SI 2217704 T1 SI2217704 T1 SI 2217704T1
Authority
SI
Slovenia
Prior art keywords
angiogenesis
vascularization
promotion
inhibition
vascular repair
Prior art date
Application number
SI200831774A
Other languages
English (en)
Slovenian (sl)
Inventor
Stefanie Dimmeler
Andreas M. Zeiher
Angelika Bonauer
Carmen Urbich
Original Assignee
T2Cure Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by T2Cure Gmbh filed Critical T2Cure Gmbh
Publication of SI2217704T1 publication Critical patent/SI2217704T1/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • C12N2310/113Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/50Methods for regulating/modulating their activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SI200831774A 2007-10-30 2008-10-30 Postopek za pospeševanje angiogeneze, vaskularizacije ali popravilo žil ali za zaviranje tumorske angiogeneze SI2217704T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102007052114A DE102007052114B4 (de) 2007-10-30 2007-10-30 Verfahren zur Modulation der Funktion, des Wachstums oder der Differenzierung einer Zelle
EP08844273.6A EP2217704B1 (de) 2007-10-30 2008-10-30 Verfahren zur förderung der angiogenese, vaskularisierung oder gefässreparatur oder zur hemmung der tumorangiogenese
PCT/DE2008/001759 WO2009056116A1 (de) 2007-10-30 2008-10-30 Verfahren zur förderung der angiogenese, vaskularisierung oder gefässreparatur oder zur hemmung der tumorangiogenese

Publications (1)

Publication Number Publication Date
SI2217704T1 true SI2217704T1 (sl) 2017-05-31

Family

ID=40375407

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200831774A SI2217704T1 (sl) 2007-10-30 2008-10-30 Postopek za pospeševanje angiogeneze, vaskularizacije ali popravilo žil ali za zaviranje tumorske angiogeneze
SI200831894T SI2684955T1 (en) 2007-10-30 2008-10-30 A method for promoting angiogenesis, vascular or repair of the vessels, or for inhibiting tumor angiogenesis

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI200831894T SI2684955T1 (en) 2007-10-30 2008-10-30 A method for promoting angiogenesis, vascular or repair of the vessels, or for inhibiting tumor angiogenesis

Country Status (16)

Country Link
US (4) US8258113B2 (OSRAM)
EP (3) EP2684956B1 (OSRAM)
JP (4) JP5898843B2 (OSRAM)
CA (1) CA2704290C (OSRAM)
CY (2) CY1120360T1 (OSRAM)
DE (1) DE102007052114B4 (OSRAM)
DK (2) DK2684955T3 (OSRAM)
ES (2) ES2651287T3 (OSRAM)
HR (2) HRP20170346T1 (OSRAM)
HU (2) HUE037494T2 (OSRAM)
LT (2) LT2684955T (OSRAM)
NO (1) NO2684955T3 (OSRAM)
PL (2) PL2217704T3 (OSRAM)
PT (2) PT2684955T (OSRAM)
SI (2) SI2217704T1 (OSRAM)
WO (1) WO2009056116A1 (OSRAM)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030376A1 (it) 2003-07-31 2005-02-01 Univ Roma Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia.
US11660317B2 (en) 2004-11-08 2023-05-30 The Johns Hopkins University Compositions comprising cardiosphere-derived cells for use in cell therapy
HUE037173T2 (hu) 2006-08-08 2018-08-28 Univ Bonn Rheinische Friedrich Wilhelms 5'-Foszfát-oligonukleotidok szerkezete és alkalmazása
DE102007052114B4 (de) 2007-10-30 2011-01-05 T2Cure Gmbh Verfahren zur Modulation der Funktion, des Wachstums oder der Differenzierung einer Zelle
US9738680B2 (en) 2008-05-21 2017-08-22 Rheinische Friedrich-Wilhelms-Universität Bonn 5′ triphosphate oligonucleotide with blunt end and uses thereof
US9249392B2 (en) 2010-04-30 2016-02-02 Cedars-Sinai Medical Center Methods and compositions for maintaining genomic stability in cultured stem cells
US9845457B2 (en) 2010-04-30 2017-12-19 Cedars-Sinai Medical Center Maintenance of genomic stability in cultured stem cells
WO2012065024A1 (en) * 2010-11-11 2012-05-18 University Of Miami Compositions, cells, kits and methods for autologous stem cell therapy
EP2508530A1 (en) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Purification of triphosphorylated oligonucleotides using capture tags
US9884076B2 (en) 2012-06-05 2018-02-06 Capricor, Inc. Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy
CN104685056A (zh) 2012-06-21 2015-06-03 米拉根医疗股份有限公司 包含锁核酸基序的基于寡核苷酸的抑制剂
EP2882445B1 (en) 2012-08-13 2019-04-24 Cedars-Sinai Medical Center Exosomes and micro-ribonucleic acids for tissue regeneration
EP2712870A1 (en) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Novel RIG-I ligands and methods for producing them
EP2759595B1 (en) * 2013-01-24 2016-09-14 Pierre Fabre Médicament S.A.S. Composition comprising an encapsulated antagomir
WO2014145356A1 (en) 2013-03-15 2014-09-18 MiRagen Therapeutics, Inc. Bridged bicyclic nucleosides
US11253549B2 (en) 2014-05-23 2022-02-22 JangoBio, LLC Methods to rebalance the hypothalamic-pituitary-gonadal axis
US11439668B2 (en) 2014-05-23 2022-09-13 JangoBio, LLC Methods to differentiate stem cells into hormone-producing cells
CA2962444C (en) 2014-10-03 2023-09-05 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
US20160122762A1 (en) * 2014-10-27 2016-05-05 University Of Iowa Research Foundation Methods of treating atherosclerosis
HK1249108A1 (zh) * 2015-01-20 2018-10-26 米拉根医疗股份有限公司 Mir-92抑制剂及其用途
WO2017123662A1 (en) 2016-01-11 2017-07-20 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction
US11351200B2 (en) 2016-06-03 2022-06-07 Cedars-Sinai Medical Center CDC-derived exosomes for treatment of ventricular tachyarrythmias
CN107586784B (zh) * 2016-07-08 2020-08-25 田小利 一种分离的rnasek基因及其在制备抗血管衰老药物中的应用
EP3515459A4 (en) 2016-09-20 2020-08-05 Cedars-Sinai Medical Center CELLS DERIVED FROM CARDIOSPHERES AND THEIR EXTRACELLULAR VESICLES TO DELAY OR REVERSE AGING AND AGE-RELATED DISORDERS
US11759482B2 (en) 2017-04-19 2023-09-19 Cedars-Sinai Medical Center Methods and compositions for treating skeletal muscular dystrophy
US11660355B2 (en) 2017-12-20 2023-05-30 Cedars-Sinai Medical Center Engineered extracellular vesicles for enhanced tissue delivery
EP3749344A4 (en) 2018-02-05 2022-01-26 Cedars-Sinai Medical Center METHODS OF THERAPEUTIC USE OF EXOSOMES AND Y-RNAS
WO2019167995A1 (ja) * 2018-02-28 2019-09-06 国立大学法人東京医科歯科大学 虚血病変部位特異的な遺伝子治療法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1648914A4 (en) * 2003-07-31 2009-12-16 Regulus Therapeutics Inc OLIGOMERIC COMPOUNDS AND COMPOSITIONS USEFUL FOR MODULATING SMALL NON-CODING RNA
AU2005250432B2 (en) * 2004-05-28 2011-09-15 Asuragen, Inc. Methods and compositions involving microRNA
EP1904111A4 (en) * 2005-06-03 2009-08-19 Univ Johns Hopkins COMPOSITIONS AND METHODS FOR REDUCING MICRORNA EXPRESSION FOR THE TREATMENT OF NEOPLASIA
EP2455492B1 (en) * 2006-07-13 2013-11-20 The Ohio State University Research Foundation Micro-RNA-based methods and compositions for the diagnosis and treatment of colon related diseases
US8466117B2 (en) * 2006-07-28 2013-06-18 The Johns Hopkins University Compositions and methods for modulating angiogenesis
WO2008070082A2 (en) * 2006-12-04 2008-06-12 The Johns Hopkins University Stem-progenitor cell specific micro-ribonucleic acids and uses thereof
WO2009004632A2 (en) * 2007-07-05 2009-01-08 Yeda Research And Development Co. Ltd. Methods of identifying components of a biological pathway and use of said components in regulating diseases associated with altered cell proliferation
WO2009012468A2 (en) * 2007-07-18 2009-01-22 The Regents Of The University Colorado Differential expression of micrornas in nonfailing versus failing human hearts
DE102007052114B4 (de) 2007-10-30 2011-01-05 T2Cure Gmbh Verfahren zur Modulation der Funktion, des Wachstums oder der Differenzierung einer Zelle

Also Published As

Publication number Publication date
CY1120226T1 (el) 2018-12-12
JP2014196317A (ja) 2014-10-16
EP2684955A1 (de) 2014-01-15
EP2217704A1 (de) 2010-08-18
PL2684955T3 (pl) 2018-05-30
JP5898843B2 (ja) 2016-04-06
HRP20170346T1 (hr) 2017-04-21
JP2011500858A (ja) 2011-01-06
HUE037494T2 (hu) 2018-08-28
SI2684955T1 (en) 2018-01-31
US20100324118A1 (en) 2010-12-23
HUE031559T2 (hu) 2017-07-28
PT2684955T (pt) 2017-12-13
HRP20171874T1 (hr) 2018-01-12
DE102007052114B4 (de) 2011-01-05
EP2684956B1 (de) 2017-08-23
LT2217704T (lt) 2017-04-10
US20120322856A1 (en) 2012-12-20
EP2684956A1 (de) 2014-01-15
US20160237433A1 (en) 2016-08-18
PT2217704T (pt) 2017-03-15
EP2217704B1 (de) 2016-12-07
DK2217704T3 (en) 2017-03-13
WO2009056116A1 (de) 2009-05-07
US9279123B2 (en) 2016-03-08
JP2018083817A (ja) 2018-05-31
US8912158B2 (en) 2014-12-16
PL2217704T3 (pl) 2017-06-30
EP2684955B1 (de) 2017-09-06
ES2651287T3 (es) 2018-01-25
DE102007052114A1 (de) 2009-05-07
ES2618203T3 (es) 2017-06-21
LT2684955T (lt) 2017-12-27
NO2684955T3 (OSRAM) 2018-02-03
CY1120360T1 (el) 2019-07-10
CA2704290A1 (en) 2009-05-07
US8258113B2 (en) 2012-09-04
CA2704290C (en) 2018-05-15
JP2016199565A (ja) 2016-12-01
DK2684955T3 (en) 2017-12-18
US20150018407A1 (en) 2015-01-15
US9862949B2 (en) 2018-01-09

Similar Documents

Publication Publication Date Title
LT2217704T (lt) Būdas, skirtas angiogenezės, vaskuliarizacijos arba kraujagyslių gijimo skatinimui arba naviko angiogenezės slopinimui
AP2010005508A0 (en) Triazole derivatives useful for the treatment of diseases.
PT2509958E (pt) Derivados de azol, métodos para produzir os mesmos, seus intermediários, agentes de agro-horticultura
AP2011005760A0 (en) Tobacco curing method.
BRPI1008021A2 (pt) Método para fabricação de 2,6-dioxabiciclo-(3.3.0)-octano-4,8-diona
ZA200904860B (en) Combination therapy with angiogenesis inhibitors
GB0912562D0 (en) LXR-antagonists for the prevention, reduction or inhibition of scarring
EP2352515A4 (en) METHOD FOR TREATING HEMOPHILIA
AP00227S1 (en) Pump liner.
EP2326381A4 (en) DISTAL PART FOR MONORAIL CATHETER
FI20085962A0 (fi) Menetelmä raudan erottamiseksi
IL210066A0 (en) Novel ortho-aminoanilides for the treatment of cancer
IL180221A0 (en) Improved rapid-exchange catheter
PL2155679T3 (pl) Sposób wytwarzania pochodnych 4-formyloaminopiperydyny
PL2103401T3 (pl) Instalacja do produkcji wyrobów ceramicznych
LU91562B1 (en) Hydroquinone derivatives.
PL2391366T3 (pl) Podstawione benzimidazole do leczenia gwiaździaków
EP2211871A4 (en) METHOD FOR INHIBITING ANGIOGENESIS OR TREATING CANCER
PL2286029T3 (pl) Sposób usuwania tłucznia z toru
AP2011005893A0 (en) Thia-triaza-cyclopentazulenes as P13-kinases inhibitors for the treatment of cancer.
GB2476644B (en) 1,4-Dihydro-1,4-dioxonaphtalene derivatives for the treatment of osteoporosis
ZA201004090B (en) Methods for the inhibition of scarring
TWI365721B (en) Method of improve the drying rate of freeze-drying
GB0703238D0 (en) Lift pit liner process specification
IL199931A0 (en) Method for the production of 2,4-dihydroxyphenyl-4-methoxybenzyl ketones